Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.245
Neutral
RSI(14)
57.017
Neutral
STOCH(KDJ)(9,3,3)
59.945
Sell
ATR(14)
5.596
Low Volatility
CCI(14)
34.738
Neutral
Williams %R
35.482
Buy
TRIX(12,20)
0.711
Sell
StochRSI(14)
0.000
Sell
Search
Liquidia Corp
LQDAAdd to Watchlist
84.110USD
-2.690-3.10%
Close 07-31 16:00（ET）Quotes delayed by 15 min
7.48BMarket Cap
336.13P/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-3.10%
5 Days
-2.45%
1 Month
+5.49%
6 Months
+98.42%
Year to Date
+143.87%
1 Year
+350.03%
Key Figures
86.240Open
87.460High
1.13MVolume
336.13P/E TTM
12.27P/E Dynamic
--Dividend TTM
1.30%Turnover Ratio
86.800Prev. Close
82.530Low
75.06MTurnover
LossP/E Static
331.14P/B
0.00%Div Yield TTM
7.09%ROA
46.67052wk High
0.83Volume Ratio
-130.39MNet Profit
86.82MShares
0.2502EPS TTM
0.41Beta
28.18%ROE
11.26052wk Low
5.68%Amplitude
91.08%Gross Margin
7.48BMarket Cap
2.53Reward/Risk
3.94%Risk Rate
TradingKey Stock Score of Liquidia Corp
Currency: USD Updated: 2026-07-31Key Insights
Liquidia Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 38 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 83.99.In the medium term, the stock price is expected to trend up.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Liquidia Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Liquidia Corp Highlights
StrengthsRisks
Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 805.31% year-on-year.
Overvalued
The company’s latest PE is 336.13, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 65.17M shares, decreasing 9.44% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 34.18K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.16.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
83.987
Target Price
-3.26%
Upside Space
Liquidia Corp News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
9
analysts
Buy
Current Rating
83.987
Target Price
-3.26%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Liquidia Corp
LQDA
9
Amgen Inc
AMGN
37
Biogen Inc
BIIB
37
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
32
Pfizer Inc
PFE
32
1
2
3
...
32
Indicators
Moving Average
Indicators
Value
Direction
MA5
85.794
Sell
MA10
84.923
Sell
MA20
81.459
Buy
MA50
73.253
Buy
MA100
56.971
Buy
MA200
44.936
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Liquidia Corp Info
Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
Ticker SymbolLQDA
CompanyLiquidia Corp
CEOJeffs (Roger A)
Websitehttps://www.liquidia.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-2.51%
+0.32%
-1.45%
-0.92%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
-0.90%
+1.30%
-2.15%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of Liquidia Corp (LQDA)?
The current price of Liquidia Corp (LQDA) is 84.11.
What is the symbol of Liquidia Corp?
The ticker symbol of Liquidia Corp is LQDA.
What is the 52-week high of Liquidia Corp?
The 52-week high of Liquidia Corp is 46.67.
What is the 52-week low of Liquidia Corp?
The 52-week low of Liquidia Corp is 11.26.
What is the market capitalization of Liquidia Corp?
The market capitalization of Liquidia Corp is 7.30B.
Is Liquidia Corp (LQDA) currently rated as Buy, Hold, or Sell?
According to analysts, Liquidia Corp (LQDA) has an overall rating of Buy, with a price target of 83.99.
What is the Earnings Per Share (EPS TTM) of Liquidia Corp (LQDA)?
The Earnings Per Share (EPS TTM) of Liquidia Corp (LQDA) is -0.80.